SCHEMBL298860

SCHEMBL298860

O=C(c1cc(NS(=O)(=O)c2cccc(F)c2)ccc1F)c1c[nH]c2ncccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.54
CYP2C9 P11712 4/20 0.51
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
BRAF P15056 2/20 0.44
ALDH1A1 P00352 1/20 0.44
KIT P10721 1/20 0.44
CDC7 O00311 1/20 0.42
ROCK2 O75116 1/20 0.42
MAP4K4 O95819 1/20 0.42
PIM1 P11309 1/20 0.42
PRKACA P17612 1/20 0.42
CDK2 P24941 1/20 0.42
GSK3B P49841 1/20 0.42
HIPK2 Q9H2X6 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
AURKA O14965 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL298904 0.91 CYP3A4 (0.47) CYP3A4CYP2C9SMN1; SMN2BRAFALDH1A1
SCHEMBL298074 0.90 CLK1 (0.46) CYP3A4CYP2C9LMNABRAFALDH1A1
SCHEMBL298650 0.89 BRAF (0.51) CYP3A4LMNASMN1; SMN2BRAFKIT
SCHEMBL858685 0.88 CYP3A4 (0.59) CYP3A4CYP2C9BRAFKITMAP4K4
SCHEMBL298469 0.87 ALDH1A1 (0.47) CYP3A4BRAFALDH1A1KITKMT2A
SCHEMBL298424 0.87 SLC40A1 (0.48) CYP3A4CYP2C9BRAFKITMAP2K1
SCHEMBL298047 0.85 BRAF (0.56) CYP3A4CYP2C9BRAFKITCYP2C19
SCHEMBL297491 0.84 BRAF (0.51) CYP3A4CYP2C9BRAFCDK2GSK3B
SCHEMBL299744 0.83 CCR9 (0.51) CYP3A4BRAFMAP2K1FABP4FABP5
SCHEMBL298354 0.82 CYP3A4 (0.53) CYP3A4CYP2C9BRAFKITMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF CYP3A4 3611/4885CYP2C9 2176/4885LMNA 3902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.